Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy

NCT02606136 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT02606136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02606136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Lead sponsor
Kyntra Bio
Phase
Phase 2
Overall status
Terminated
Start date
January 4, 2016
Completion date
August 9, 2023
Enrollment
21 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy